Walvax BioTech (300142) — Capital Reinvestment Ratio
Latest as of June 2025:
0.26x
Walvax BioTech (300142) has a Capital Reinvestment Ratio of 0.26x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥278.33 Million) in capital expenditures (CN¥71.03 Million). See Walvax BioTech free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.26x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥278.33 Million
CNY
Capital Expenditures
CN¥71.03 Million
CNY
Data as of
Jun 2025
Most recent filing
Walvax BioTech Capital Reinvestment Ratio (2007–2025)
This chart tracks Walvax BioTech's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Walvax BioTech (2007–2025)
Year-by-year Capital Reinvestment Ratio for Walvax BioTech from 2007 to 2025. For live market cap and broader valuation context, see how much is Walvax BioTech worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.03x | CN¥494.37 Million | CN¥509.54 Million | ▲ +94.2% |
| 2024 | 0.53x | CN¥1.04 Billion | CN¥550.03 Million | ▼ -36.4% |
| 2023 | 0.83x | CN¥1.13 Billion | CN¥945.52 Million | ▼ -8.2% |
| 2022 | 0.91x | CN¥1.20 Billion | CN¥1.09 Billion | ▼ -42.0% |
| 2021 | 1.56x | CN¥705.28 Million | CN¥1.10 Billion | ▼ -56.1% |
| 2020 | 3.57x | CN¥114.19 Million | CN¥407.13 Million | ▼ -37.2% |
| 2019 | 5.67x | CN¥62.02 Million | CN¥351.82 Million | ▲ +24.9% |
| 2012 | 4.54x | CN¥78.38 Million | CN¥355.87 Million | ▲ +111.4% |
| 2011 | 2.15x | CN¥91.98 Million | CN¥197.56 Million | ▲ +13.0% |
| 2010 | 1.90x | CN¥86.71 Million | CN¥164.81 Million | ▲ +109.0% |
| 2009 | 0.91x | CN¥82.18 Million | CN¥74.75 Million | ▲ +58.7% |
| 2007 | 0.57x | CN¥31.85 Million | CN¥18.26 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow